<DOC>
	<DOCNO>NCT00004216</DOCNO>
	<brief_summary>RATIONALE : Biological therapy VNP20009 use different way stimulate immune system stop cancer cell grow . PURPOSE : Phase I trial study effectiveness VNP20009 treat patient advanced metastatic solid tumor respond previous therapy .</brief_summary>
	<brief_title>VNP20009 Treating Patients With Advanced Metastatic Solid Tumors That Have Not Responded Previous Therapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose safety intratumoral live , genetically modify Salmonella typhimurium ( VNP20009 ) patient refractory , superficial solid tumor . II . Determine efficacy VNP20009 patient . OUTLINE : This dose-escalation study . Patients receive intratumorally inject live , genetically modify Salmonella typhimurium ( VNP20009 ) day 0 . The tumor biopsied day 14 . Cohorts 3-6 patient receive escalate dos VNP20009 maximum tolerate dose ( MTD ) optimal biologic dose ( OBD ) determine . The MTD define high dose 1 patient cohort 6 experience dose-limiting toxicity ( DLT ) . The OBD define dose 3-6 patient cohort great 10 million colony-forming unit VNP20009 per gram tumor biopsy . Prior reach OBD , 2 3 additional patient may enter previous dose level show safe undergo biopsy inject lesion day 5 8 . Patients assessed systemic tumor response 4-5 week treatment . If inject lesion stable responding , non-injected lesion grow , patient may receive 2 additional course treatment . Patients receive one follow antibiotic regimen upon evidence progressive disease , DLT , discontinuation study : First line : Ciprofloxacin IV orally every 12 hour day 1 orally twice day 18 day Second line : Ceftriaxone IV day 1 cefixime orally 16 day Third line : Co-trimoxazole orally twice day 21 day Patients follow additional 4 week initiation antibiotic therapy . PROJECTED ACCRUAL : A total 12-40 patient accrue study .</detailed_description>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Cefixime</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven advanced metastatic solid tumor fail prior therapy therapy available At least 1 tumor mass size make intratumoral injection feasible biopsy fine needle aspiration possible Major surgery cancer require No lymphoma No concurrent brain metastasis ( previously treat brain metastasis evidence recurrence allow ) PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Performance status : Karnofsky 70100 % OR ECOG 01 Life expectancy : At least 3 month Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hematocrit least 30 % ( transfusion allow ) No bleed disorder Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ALT/AST great 1.5 time ULN ( 3 time ULN presence liver metastasis ) Alkaline phosphatase great 1.5 time ULN ( 3 time ULN presence liver metastasis ) PT aPTT great 1.5 time ULN No end stage liver disease Renal : Creatinine great 1.5 time ULN No urinary tract stone No end stage renal disease Cardiovascular : No known valvular disease ischemic peripheral vascular disease No clinically significant atherosclerotic disease arterial aneurysm ( ) No unstable angina No active coronary artery disease require medication No myocardial infarction within past 6 month No congenital heart failure cardiac arrhythmia require medication Pulmonary : No severe oxygendependent chronic obstructive pulmonary disease Other : HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Permanent central venous catheter indwell device allow easily remove replace No gallstones No active infection No Salmonella infection within past 6 month No fever cause tumor unknown cause ( daily temperature great 38 degree C ) No immunodeficiency No lifethreatening illness No commercial food handler , daycare worker , healthcare worker plan continue employment protocol treatment No allergy quinolone cephalosporin antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 month since prior bone marrow transplantation At least 4 week since prior biologic therapy recover No concurrent biologic therapy No prior allogeneic transplant Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy Endocrine therapy : At least 2 week since prior hormonal therapy No concurrent steroid Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : See Disease Characteristics At least 2 week since prior surgery recover No artificial implant ( e.g. , heart valve prosthetic hip knee ) No prior splenectomy Other : No concurrent antibiotics No concurrent immunosuppressives No concurrent medication directly indirectly suppress immune system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>